SomaLogic to provide 210 million protein measurements to EPIC researchers to better understand and predict cancer development
SomaLogic (NASDAQ: SLGC) announced it will begin analyzing samples from the EPIC study in Q1 2022 using its SomaScan® Assay. This collaboration aims to develop predictive protein markers in cancer, potentially enhancing diagnostic tools. The EPIC study, one of the largest global cohort studies with 521,000 participants, focuses on the impact of diet and lifestyle on cancer incidence. SomaLogic's efforts, in conjunction with Imperial College London, will create a Centre for Excellence in Proteomics of Cancer, furthering research into chronic diseases.
- SomaLogic's collaboration with EPIC enhances its research capabilities in cancer detection.
- The partnership aims to develop predictive protein markers, potentially improving cancer diagnostics.
- Creation of a Centre for Excellence in Proteomics of Cancer indicates strong institutional support.
- None.
BOULDER, Colo., March 21, 2022 (GLOBE NEWSWIRE) -- SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the European Prospective Investigation into Cancer and Nutrition (EPIC) study beginning in the first quarter of 2022. SomaLogic will use its industry leading SomaScan® Assay to analyze 210 million protein measurements from 30,000 samples spanning 15 years of clinical interactions to help researchers understand and predict cancer development. The SomaScan® Platform is the first large-scale, multi-disease proteomics study to be conducted in the EPIC cohort.
Substantial progress has been made over the past two decades in clinical diagnosis and survival for a range of cancers, but population screening programs have not kept pace with these advances. The collaboration between SomaLogic and EPIC aims to develop potentially predictive protein markers in cancer and other diseases. This may lead to fundamental discoveries enhancing clinical understanding of cancer and its treatment, or to the development of screening and diagnostic tools to improve outcomes.
Through its collaboration with EPIC, SomaLogic and Imperial College London will create a Centre for Excellence in Proteomics of Cancer, which will sit within the School of Public Health and continue research into areas of chronic disease supported by proteomic analysis.
“Proteomics is a powerful tool in predicting cancer because of its strengths in detecting immune surveillance and the body’s response to precancer physiology and environmental exposures,” said SomaLogic Chief Medical Officer Stephen A. Williams. “EPIC’s rich data set will allow us the chance to explore new ways of predicting cancer.”
Jointly coordinated by the World Health Organization’s International Agency for Research on Cancer and Imperial College London, the EPIC study is one of the largest cohort studies in the world with 521,000 participants recruited from 10 European countries and follow-up data covering 20 years. The study is focused on the impact of diet, nutritional status, and lifestyle and environmental factors on the incidence of various cancers and other chronic diseases, such as cardiovascular diseases, osteoporosis and neurodegenerative diseases. Over the EPIC study period of 1992 to 2015, more than 67,000 participants were diagnosed with cancer. Updating the follow-up data is on-going.
“The study of proteins is the missing ‘-omic’ in the study of cancer,” said EPIC Coordinator and Principal Investigator Elio Riboli, a Professor of Cancer Epidemiology and Prevention at Imperial College London’s School of Public Health. “Having proteomic measurements in our data gives us the strongest case for the integration of genetics, behavior and environment in improving the prediction of disease.”
SomaLogic is currently working with researchers from 22 large databanks from around the world to provide proteomics data to support the study of human health. SomaLogic will use the SomaScan data from the EPIC study, as well as information from clinical visits and health histories, to develop tools to improve cancer care.
About SomaLogic
SomaLogic (Nasdaq: SLGC) seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.
SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory.
About Imperial College London
Imperial College London is one of the world's leading universities. The College's 20,000 students and 8,000 staff are working to solve the biggest challenges in science, medicine, engineering and business. Imperial is University of the Year 2022 in the Times and Sunday Times Good University Guide. It is the world’s fifth most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry. Imperial staff, students and alumni are working round-the-clock to combat COVID-19. Imperial is at the forefront of coronavirus epidemiology, virology, vaccine development and diagnostics.
http://www.imperial.ac.uk/
SomaLogic Contact
Emilia Costales
720-798-5054
ecostales@somalogic.com
Investor Contact
Lynn Lewis or Marissa Bych
Gilmartin Group LLC
investors@somalogic.com
FAQ
What is the recent press release about SomaLogic (SLGC)?
When will SomaLogic begin analyzing samples from the EPIC study?
What technology is SomaLogic using for the EPIC study?
How many participants are involved in the EPIC study?
What is the purpose of the collaboration between SomaLogic and EPIC?
